Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
This is a phase II trial in patients with 1-2 brain metastases treated with surgical
resection followed by stereotactic radiosurgery boost. Following surgical resection,
patients would receive a stereotactic radiosurgery boost to the surgical bed, 2-8 weeks
after surgery. A dose of 15 to 22 Gy would be delivered in a single fraction. Patient would
be subsequently followed clinically and radiologically to watch for local control as well as
toxicity. If a recurrence or new metastasis(es) is detected, further treatment may be given,
consisting of chemotherapy, surgery, whole brain radiation therapy or stereotactic
radiotherapy.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the local control following a combination of stereotactic radiosurgery and surgical resection for brain metastases; to determine the incidence of the brain injury following the combination therapy
1 year
Yes
Kathryn Beal, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
04-061
NCT00587964
June 2004
January 2009
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |